Review article: Medical management of the liver transplant recipient - A primer for non-transplant doctors

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2007, Pages 229-245

  Sethi, A ^a   Stravitz, R T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE; AMIODARONE; AMLODIPINE; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DILTIAZEM; ETHINYLESTRADIOL; MACROLIDE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFCILLIN; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER RISK; CHRONIC KIDNEY FAILURE; COLON CARCINOMA; DIABETES MELLITUS; DIURETIC THERAPY; DRUG DOSE REDUCTION; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS CARCINOMA; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GRAFT RECIPIENT; GYNECOLOGIC CANCER; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION RISK; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE DAMAGE; LIFESTYLE MODIFICATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG CARCINOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEPHROTOXICITY; OBESITY; OROPHARYNX CARCINOMA; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PERIPHERAL EDEMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RENOVASCULAR DISEASE; REVIEW; SKIN CARCINOMA; SOLID TUMOR; TACHYCARDIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; VASCULAR DISEASE;

HUMANS; LIVER TRANSPLANTATION; LONG-TERM CARE; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SURVIVAL RATE;

EID: 33846323973     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03166.x     Document Type: Review

References (151)

1. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886-97.
2. McCashland TM. Posttransplantation care: role of the primary care physician versus transplant center. Liver Transpl 2001; 7 (11 Suppl. 1): S2-12.
3. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811-5.
4. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595-9.
5. Neal DA, Brown MJ, Wilkinson IB, Alexander GJ. Mechanisms of hypertension after liver transplantation. Transplantation 2005; 79: 935-40.
6. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving > or =5 years after liver transplant. Transplantation 2000; 69: 781-9.
7. Everson GT, Trouillot T, Wachs M, et al. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 1999; 5 (4 Suppl. 1): S48-57.
8. Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230: 441-8.
9. Piscaglia F, Zironi G, Gaiani S, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999; 30: 58-64.
10. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6: 521-30.
11. Munoz SJ, Rothstein KD, Reich D, Manzarbeitia C. Long-term care of the liver transplant recipient. Clin Liver Dis 2000; 4: 691-710.
12. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-92.
13. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693-9.
14. Lerman A, Click RL, Narr BJ, et al. Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation 1991; 51: 646-50.
15. Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997; 52: 248-60.
16. Canzanello VJ, Textor SC, Taler SJ, et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998; 4: 328-34.
17. Devlin J, Williams R, Neuhaus P, et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. Transpl Int 1994; 7 (Suppl. 1): S22-6.
18. Hricik DE, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232-5.
19. Munoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005; 11 (11 Suppl. 2): S52-6.
20. Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004; 77: 748-50.
21. Galioto A, Angeli P, Guarda S, et al. Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. Transplant Proc 2005; 37: 1245-7.
22. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-40.
23. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59-66.
24. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-9.
25. Brown RS Jr, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62: 1788-93.
26. Gayowski T, Singh N, Keyes L, et al. Late-onset renal failure after liver transplantation: role of posttransplant alcohol use. Transplantation 2000; 69: 383-8.
27. Reich D, Rothstein K, Manzarbeitia C, Munoz S. Common medical diseases after liver transplantation. Semin Gastrointest Dis 1998; 9: 110-25.
28. Wilkinson AH, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver Transpl 2006; 11: S47-51.
29. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741-7.
30. Campbell MS, Kotlyar DS, Brensinger CM, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005; 11: 1048-55.
31. Velidedeoglu E, Crawford MD, Desai NM, et al. Predictors of late kidney dysfunction post-liver transplantation. Transplant Proc 2002; 34: 3315-6.
32. Shokouh-Amiri MH, Egidi MF, Lo A, et al. The importance of early prevention of renal dysfunction in liver transplant recipients. Transplant Proc 2001; 33: 1399-400.
33. Abrahamian GA, Cosimi AB, Farrell ML, Schoenfeld DA, Chung RT, Pascual M. Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transpl 2000; 6: 185-90.
34. Cotterell AH, Fisher RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16 (Suppl. 7): 49-51.
35. Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-91.
36. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75: 186-90.
37. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004; 10: 1189-94.
38. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079-85.
39. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126-9.
40. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35 (Suppl. 3): 209S-16S.
41. Gonwa TA, Mai ML, Klintmalm GB. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 2563-5.
42. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996; 25: 64-71.
43. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8: 708-13.
44. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 2005; 11: 612-20.
45. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-6.
46. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-72.
47. Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90.
48. John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001; 34: 889-95.
49. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as nontransplant-associated diabetes? Transplantation 1998; 65: 380-4.
50. Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002; 74: 1007-12.
51. Marroni CA, Hoppe L, Diehl JL, et al. Diabetes mellitus and liver transplantation in adults. Transplant Proc 1999; 31: 3046.
52. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998; 4: 285-96.
53. Delgado-Borrego A, Casson D, Schoenfeld D, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703-10.
54. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402.
55. Levy G, Villamil F, Samuel D, et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-8.
56. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26: 30-3.
57. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting, Barcelona, Spain, 19 February 2003. Transplantation 2003; 75 (Suppl. 10): SS3-24.
58. Mathe D, Adam R, Malmendier C, et al. Prevalence of dyslipidemia in liver transplant recipients. Transplantation 1992; 54: 167-70.
59. Gisbert C, Prieto M, Berenguer M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3: 416-22.
60. Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11: 60-5.
61. Guckelberger O, Mutzke F, Glanemann M, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006; 12: 394-401.
62. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-73.
63. Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3: 1-9.
64. McCashland TM, Donovan JP, Amelsberg A, et al. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. Hepatology 1994; 19: 1381-9.
65. Rayyes OA, Wallmark A, Floren CH. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology 1996; 24: 613-9.
66. Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 401-8.
67. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35 (Suppl. 3): 193S-200S.
68. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35 (Suppl. 3): 143S-50S.
69. Fernandez-Miranda C, de la CA, Morales JM, et al. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study. Clin Transplant 1998; 12: 136-41.
70. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
71. Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001; 7: 533-9.
72. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89: 1374-80.
73. Imagawa DK, Dawson S III, Holt CD, et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxymethylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 1996; 62: 934-42.
74. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367-78.
75. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559-64.
76. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6: 770-4.
77. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006; 8: 804-7.
78. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
79. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin 2006; 22: 417-25.
80. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7: 415-33.
81. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
82. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69: 321-6.
83. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342-7.
84. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000; 12: 931-5.
85. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-66.
86. Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005; 11: 960-6.
87. Floreani A, Mega A, Tizian L, et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 2001; 12: 749-54.
88. Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am J Med 1994; 97: 445-50.
89. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
90. Giannini S, Nobile M, Dalle CL, et al. Vertebral morphometry by X-ray absorptiometry before and after liver transplant: a cross-sectional study. Eur J Gastroenterol Hepatol 2001; 13: 1201-7.
91. Hamburg SM, Piers DA, van den Berg AP, Slooff MJ, Haagsma EB. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11: 600-6.
92. Abdelhadi M, Eriksson SA, Ljusk ES, Ericzon BG, Nordenstrom J. Bone mineral status in end-stage liver disease and the effect of liver transplantation. Scand J Gastroenterol 1995; 30: 1210-5.
93. Giannini S, Nobile M, Ciuffreda M, et al. Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 2000; 11: 417-24.
94. Monegal A, Navasa M, Guanabens N, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001; 12: 484-92.
95. Hussaini SH, Oldroyd B, Stewart SP, et al. Regional bone mineral density after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 1999; 11: 157-63.
96. Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 1999; 5: 407-13.
97. Gong Z, Wezeman FH. Inhibitory effect of alcohol on osteogenic differentiation in human bone marrow-derived mesenchymal stem cells. Alcohol Clin Exp Res 2004; 28: 468-79.
98. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000; 95: 2343-51.
99. Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RA, LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257-61.
100. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003; 9: 321-30.
101. Monegal A, Navasa M, Guanabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68: 83-6.
102. Smallwood GA, Burns D, Fasola CG, Steiber AC, Heffron TG. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic. Transplant Proc 2005; 37: 1910-1.
103. Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int 2005; 18: 1028-35.
104. Romero DF, Buchinsky FJ, Rucinski B, et al. Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 1995; 10: 760-8.
105. Goodman GR, Dissanayake IR, Sodam BR, et al. Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 2001; 16: 72-8.
106. Dissanayake IR, Goodman GR, Bowman AR, et al. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275-8.
107. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995; 57: 15-9.
108. Riemens SC, Oostdijk A, van Doormaal JJ, et al. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. Osteoporos Int 1996; 6: 213-8.
109. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998; 4: 404-9.
110. Vedi S, Ninkovic M, Garrahan NJ, Alexander GJ, Compston JE. Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. Transpl Int 2002; 15: 290-5.
111. Dodidou P, Bruckner T, Hosch S, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003; 14: 82-9.
112. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 2002; 37: 93-100.
113. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 239-48.
114. Isoniemi H, Appelberg J, Nilsson CG, Makela P, Risteli J, Hockerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 2001; 34: 299-305.
115. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001; 7 (11 Suppl. 1): S109-18.
116. Rabkin JM, de la Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2001; 181: 475-9.
117. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91.
118. Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW. Tumors and transplantation: The 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003; 3: 1481-7.
119. Kenngott S, Gerbes AL, Schauer R, Bilzer M. Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transpl Int 2003; 16: 639-41.
120. Kelly DM, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 1237-43.
121. Jonas S, Rayes N, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-50.
122. Maluf D, Cotterell A, Clark B, Stravitz T, Kauffman HM, Fisher RA. Hepatic angiosarcoma and liver transplantation: case report and literature review. Transplant Proc 2005; 37: 2195-9.
123. Ben Ari Z, Amlot P, Lachmanan SR, Tur-Kaspa R, Rolles K, Burroughs AK. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg 1999; 5: 184-91.
124. Boeckle E, Boesmueller C, Wiesmayr S, et al. Kaposi sarcoma in solid organ transplant recipients: a single center report. Transplant Proc 2005; 37: 1905-9.
125. Sheldon J, Henry S, Mourad M, et al. Human herpes virus 8 infection in kidney transplant patients in Belgium. Nephrol Dial Transplant 2000; 15: 1443-5.
126. Molmenti EP, Molmenti H, Weinstein J, et al. Syndromic incidence of ovarian carcinoma after liver transplantation, with special reference to anteceding breast cancer. Dig Dis Sci 2003; 48: 187-9.
127. Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005; 80: 759-64.
128. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl 2005; 11: 1100-6.
129. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000; 6: 253-62.
130. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
131. Atassi T, Thuluvath PJ. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol 2003; 37: 72-3.
132. Higashi H, Yanaga K, Marsh JW, Tzakis A, Kakizoe S, Starzl TE. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology 1990; 11: 477-80.
133. Duvoux C, Delacroix I, Richardet JP, et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 418-21.
134. Trotter JF, Brazer SR. Rapid progression to high-grade dysplasia in Barrett's esophagus after liver transplantation. Liver Transpl Surg 1999; 5: 332-3.
135. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-25.
136. Timuragaoglu A, Ugur-Bilgin A, Colak D, et al. Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc 2006; 38: 641-5.
137. George TI, Jeng M, Berquist W, Cherry AM, Link MP, Arber DA. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature. Pediatr Blood Cancer 2005; 44: 270-6.
138. Pasquale MA, Weppler D, Smith J, et al. Burkitt s lymphoma variant of post-transplant lymphoproliferative disease (PTLD). Pathol Oncol Res 2002; 8: 105-8.
139. Glez-Chamorro A, Jimenez C, Moreno-Glez E, et al. Management and outcome of liver recipients with posttransplant lymphoproliferative disease. Hepatogastroenterology 2000; 47: 211-9.
140. Dockrell DH, Strickler JG, Paya CV. Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients. Clin Infect Dis 1998; 26: 180-2.
141. Bierman PJ, Vose JM, Langnas AN, et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996; 7: 265-70.
142. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2: 52-9.
143. McCarthy M, Ramage J, McNair A, et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol 1997; 27: 1015-21.
144. Norin S, Kimby E, Ericzon BG, et al. Posttransplant lymphoma - a single-center experience of 500 liver transplantations. Med Oncol 2004; 21: 273-84.
145. Barkholt L, Linde A, Falk KI. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation. Transpl Int 2005; 18: 835-43.
146. Hezode C, Duvoux C, Germanidis G, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 1999; 30: 775-8.
147. Mazzaro C, Tirelli U, Pozzato G. Hepatitis C virus and non-Hodgkin's lymphoma 10 years later. Dig Liver Dis 2005; 37: 219-26.
148. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-7.
149. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solidorgan transplantation: influence of treatment on the clinical outcome. Transplantation 2002; 74: 1095-102.
150. Menachem Y, Safadi R, Ashur Y, Ilan Y. Malignancy after liver transplantation in patients with premalignant conditions. J Clin Gastroenterol 2003; 36: 436-9.
151. Perera GK, Child FJ, Heaton N, O'grady J, Higgins EM. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol 2006; 154: 868-72.